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ABSTRACT
Background: Breast cancer under 40 years concerns a relatively small subgroup of cases that tend to display
a more aggressive phenotype. Compatible with this, early age of onset has been known as one of clinical
characteristic of hereditary breast cancers associated with germline BRCA1 or BRCA1 mutations. As early
onset breast cancer is frequent in Indonesia, we investigated the histopathological and immunohistochemical
characteristics of early onset (< 40 years) Indonesian breast cancer patients, as such features can be used to
distinguish between BRCA and non-BRCA germline mutation carriers among these young women.
Method: Thirty-five formalin-fixed and paraffin-embedded tissue sections of young women (mean 36 years,
range 22-40 years) who underwent surgical resection at the Department of Surgery of the Sardjito Hospital
Yogyakarta were examined for pathological features, estrogen and progesterone receptor status, proliferation
as determined by Ki67 labeling, EGFR and CK5/6 and the presence of HER-2/neu and p53 protein. Additionally,
mutation analysis for BRCA1 and BRCA2 was performed in 30 young women. The control group consisted of
carcinomas from women above 50 years (mean 59.02, range 50-80 years).
Result: Carcinomas occurring in women aged below 40 years were more often advanced stage and higher
proliferating (p=0.006). Among the early onset breast cancer patients, ductal type, grade 3, ER and HER-2/neu
negativity, high Ki67 index and CK5/6 and EGFR positivity were typical for BRCA1 patients. Unfortunately, there
were no typical phenotypical features for BRCA2 carriers. However, grade I and lobular cases were never
BRCA1/2 germline mutated.
Conclusion: Early onset Indonesian breast cancer shows increased proliferation compared to late onset
patients. Within the early onset group, the strongest features pointing to a sporadic cancer seem to be grade I
and lobular differentiation. Features increasing the chance of a germline BRCA1/2 mutation are CK5/6 and EGFR
expression, p53 accumulation and high proliferation as measured by Ki67 labeling. This is potentially useful to
optimize selection of early onset breast cancer patients for BRCA1/2 mutation testing.
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INTRODUCTION
Breast cancer in patient under 40 years old is
uncommon. The National Cancer Institute’s
Surveillance, Epidemiology and End Results (SEER)
program reveals that 75% of breast tumors occur in
women age >50 years, only 6.5% in women age <40
years, and a mere 0.6% in women age <30 years.1,2
Carcinomas from younger patients tend to be more
aggressive with a higher incidence of poorly
differentiated (grade III) carcinomas and more
hormone insensitive (ER/PR negative) tumors.
Additionally, the tumors are often rapidly proliferating
and express abnormal p53.2,3,4
Of the relatively small fraction of young patients,
a disproportionally large fraction has hereditary breast
cancer. It has been known that over 80% of families
with two or more cases of premenopausal breast
cancer and two or more cases of ovarian cancer carry
a germline BRCA1 or BRCA2 mutation.5,6 Therefore,
a diagnosis of breast carcinoma at young age greatly
impacts these patients and their families.
Clinically, a hereditary basis of breast cancer
is, apart from early onset and family history of (early
onset) breast cancer, recognized by contra lateral
breast cancer, male breast cancer, and ovarian/
Fallopian tube cancer.7,8 Sometimes, however, family
history is incomplete, even in developed countries.
In Indonesia, incompleteness of family history is
common as a significant number of patients do not
seek medical treatment, families tend to be bigger,
and patients are thereby often poorly informed on
the exact medical problems in their families. So,
young age at presentation is in developing countries
even more important to indicate a potential hereditary
condition.
Genetic testing for BRCA1 and BRCA2 is
complex and time-consuming due to the large size
of both genes, and the presence of mutations
throughout their entire coding regions. Therefore, it
is important to find additional clinical or pathological
factors that could suggest the presence of BRCA1
or BRCA2 mutations in a patient.
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Several studies have compared the
characteristics of breast cancers in BRCA1 carriers
and sporadic controls. Distinct features of BRCA1-
associated tumor have been proposed, such as high
tumor grade, estrogen (ER) and progesterone
receptor (PgR) negativity9,10, accumulation of p539,10,
expression of the epidermal growth factor receptor
(EGFR)11,12,13, and absence of amplification and over
expression of HER-2/neu.14,15 Additionally, hereditary
breast cancers are preferentially of the ductal and
medullary carcinoma types.16,17 cDNA expression
analyses and expression of cytokeratins 5/6 have
suggested a basal epithelial phenotype for BRCA1
related cancers.18 However, the phenotype of BRCA2
related cancers is much less outspoken, and seems
to be in between that of BRCA1 related and sporadic
cancers.19 Whereas in Western countries most
hereditary breast cancers are BRCA1 related, the
reverse trend is seen in Indonesia where most
hereditary breast cancers seem to be BRCA2
related.20 In the current study, we therefore
investigated the histopathological and
immunohistochemical characteristics of early onset
(< 40 years) Indonesian breast cancer patients, as
such features can be used as to identify the BRCA1/
2 germline mutation carriers among these young
women. This could help to limit expensive mutation
screening to those patients at highest risk to harbor
a germline BRCA mutation.
MATERIALS AND METHODS
Tumor specimens
Formalin-fixed and paraffin-embedded tissue
sections were obtained from 35 young women (mean
age 36.11 years, range 22–40 years) who underwent
surgical resection of primary breast cancer between
2002-2004 at the Department of Surgery, Sardjito
Hospital, Yogyakarta, Indonesia. Tumors were
staged according to the 5th edition of the American
Joint Committee on Cancer TNM classification
system.21 Fourteen tumors were early stage (I/II) and
nineteen tumors presented at late stage (III/IV).
Specimens included 33 invasive ductal carcinomas
(IDCs), and 2 invasive lobular carcinomas (ILCs)
according to the WHO.22 Three tumors were classified
as Grade I, 15 as Grade II and 17 as Grade III
according to the modified Elston and Ellis grading.23
Concerning family history, 3/35 patients had a history
of breast or ovarian cancers in first-degree female
relatives and 3/35 patients had a family history
positive for other cancer types. Germline mutation
analyses of the entire coding region of BRCA1/
BRCA2 was done in 30 of these patients by pooled
denaturing gradient gel electrophoresis with direct
sequencing of aberrantly moving bands as described
before20, complemented by multiplex ligation
dependent probe amplification to detect genomic
deletions.24 There were two mutations in BRCA1
(deletion exon 13-15 and exon 16 p.Met165Ile) and
five mutations in BRCA2 (c.3040_3043del 4,
p.Met1149Ile, p.Glu699Leu, p.Leu824X all in exon
11 and c.9485-16T>C in exon 25). One of these latter
patients (AZ) had in addition to a pathogenic
c.2699_2704 delTAAATG mutation in exon 11 of
BRCA2 an unclassified variant mutation in exon 16
of BRCA1 (p.Met165Ile).
Fifty-four late onset breast cancer (>50 years)
from the same hospital were included as a control
group (mean 59.02, range 50 – 80 years). On this
series, data concerning family history, BRCA
mutation status, lymph node status, and EGFR and
CK5/6 status were lacking.
Immunohistochemistry
Immunohistochemistry was performed on 4 mm
thick sections. After deparaffination and rehydration,
endogenous peroxidase activity was blocked for 30
minutes in a methanol solution containing 0.3 %
hydrogen peroxide. After antigen retrieval in citrate
buffer (autoclave except for ER where the microwave
was used, a cooling off period of 30 minutes preceded
the incubation (overnight at 4°C) with the primary
antibodies (p53: DO7, Dako, 1:500; EGFR:
Novocastra, 1:10; ER: Dako, 1:50; PR: Novocastra,
1:50; HER-2/neu: Novocastra 1:100; Ki67: Dako,
1:40). The primary antibodies were detected using a
biotinylated rabbit anti-mouse antibody (DAKO). The
signal was amplified by avidin-biotin complex
formation and developed with diaminobenzidine
followed by counterstaining with haematoxylin,
dehydrated in alcohol and xylene and mounted. For
Ki67, p53, ER, and PR, only nuclear staining was
considered and diffuse cytoplasmic staining was
ignored, leading to an estimated percentage of
positively stained nuclei. HER-2/neu was scored
according to the HERCEPT system as negative, 1+,
2+ or 3+, and EGFR staining was scored positive
when a clear membrane staining pattern was seen.
Scoring was done blinded to BRCA1/2 mutation
status by a single experienced pathologist (PvD).
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HER-2/neu Amplification Testing
In addition to immunohistochemistry, HER-2/
neu was tested for amplification by multiplex ligation
dependent probe amplification (MLPA) as described
before.25 In short, 50- 500 ng of target DNA was
denatured and the probe mix was added afterward.
The mixture was heated and incubated overnight (16
h). Ligation was performed with the temperature
stable Ligase-65 enzyme (MRC-Holland) then was
inactivated in the thermocycler. Ligated mixture was
amplified with one unlabeled and one
carboxyfluorescein labeled PCR primers that are
complementary to the universal primer sequences.
PCR was carried out for 33 cycles. The fragments
were analyzed with an ABI model 310 capillary
sequencer (Applied Biosystems, Torrence, CA, USA)
using Genescan-TAMRA 500 size standards (Applied
Biosystems). Fragment analysis was performed
using Genescan software. DNA from Centre d’Etude
Polymorphisme duHumain (CEPH) was used as a
control sample and analyzed simultaneously with
breast cancer samples in each run. To objectify
interpretation of the fragment analysis, the relative
quantity of the amplified probes in each sample was
determined using an excel template. For this
purpose, the relative peak areas for each probe were
calculated as fractions of the sum of peak areas in a
given sample. Subsequently, the fraction of each peak
was divided by the average peak fraction of the
corresponding probe in control samples. Finally, the
values were normalized using the values obtained
for the autosomal control probes that served as a
reference for the copy number of 2.0. Cases that
showed a copy number greater than 2 for at least
two of the probes on the HER-2/neu locus could be
considered amplified. HER-2/neu was considered to
be “positive” when it was either 3+ overexpressed or
amplified by MLPA.
Statistics
Statistical analysis was carried out by SPSS
software version 11 for Windows. Continuous variables
were tested for differences between the non-mutated
and mutated cases using the Mann-Whitney test,
and discrete variables with the chi-square test using
logical classes. P-values <0.05 were considered
significant.
RESULTS
Table 1 shows the main clinic pathological
features of our early onset Indonesian breast cancer
study group compared to the control group and data
from other relevant published studies. There was high
prevalence of advanced stage, tumors with poor
differentiation, and tumors with lymph node
metastases. Most of the cancers were of the ductal
type, and special type cancers were lacking. With
regard to the immunophenotype, about half the cases
were ER and PgR positive, 30% were EGFR positive,
23% were HER-2/neu positive, and 23% were CK5/
6 positive. The mean percentages of p53 and MIB-1
positive cells were both 30%.
Comparison with control group of late onset (>50
years) breast cancer for several clinic pathologic
features (Table 1) showed that high Ki67 (>10%) was
more frequent in early onset patients (74% to 44%,
p= 0.006). Tumor stage, tumor type and ER staining
only showed tendency for significance (p=0.105,
p=0.165 and p=0.175 respectively) while the other
features showed no significance at all.
Comparison of continuous features between non-
BRCA and BRCA mutation carriers did not reveal
statistically significant differences (Table 2). Further
comparison between non-BRCA and BRCA carriers
among early onset breast cancer with regard to the
discrete histopathological features did also not show
significant differences although BRCA germline
mutation carriers had more advanced stage and had
never lobular or grade I carcinomas (Table 3), except
for family history (p=0.025) where twenty-two non-
BRCA cases all had negative family history for breast/
ovarian cancer or other tumors.
DISCUSSION
It is widely believed that breast cancer in young
women is characterized by relatively unfavorable
prognostic pathologic features. Published studies on
this issue are however not easily compared because
of differences in the age ranges, and the prognostic
features considered. The majority of epidemiological
studies have documented an adverse outcome of
breast cancer in young patients26,27 independent from
other factors.27
With these considerations in mind the present
study was undertaken to analyze some well-defined
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Table 1.  Clinicopathological Features of a Group of Early Onset (< 40 Years) Indonesian Breast Cancers
Compare to Control Group (>50 Years) and Relevant Studies
Table 2. Means of Continuous Clinicopathological Features of Early Onset Indonesian Breast Cancers
(=40 Years) According to BRCA1/2 Mutation Status. None of the Values were Statistically Significant
between BRCA Mutation Carriers and Patients Without Mutations
  No Mutation BRCA Mutation BRCA1 mutation BRCA2 Mutation 
  
N 
Mean N Mean N Mean n Mean N 
Age 30 35.96 23 36.14 7 40 2 34.6 5 
Tumor size 29 3.09 23 3.33 6 4 2 3 4 
ER 28 29.81 21 41.43 7 0 2 58 5 
PgR 28 24.95 21 24.43 7 25 2 24.2 5 
Ki67 30 25.96 23 32.14 7 20 2 37 5 
p53 29 24.23 22 53.14 7 90 2 38.4 5 
  Present Study Sidoni et al Rodrigues et al 
  Early Late Early Late Early Late 
Feature  N (%) N (%) N (%) N (%) N (%) N (%) 
Stage I/II 13 (41%) 32 (60%) nd Nd Nd Nd 
 III/IV 19 (59%) 21 (40%) nd nd Nd Nd 
  p=0.105     
Type Lobular 2 (6%) 2 (4%) 2 (4%) 1 (2%) Nd Nd 
 Ductal 33 (94%) 45 (83%) 44(88%) 45 (90%) Nd Nd 
  p=0.165     
Grade I 3 (9%) 2 (4%) 2 (4%) 4 (8%) 3 (15%) 7 (21%) 
 II 15 (43%) 19 (36%) 27 (58%) 36 (75%) 9 (45%) 14 (41%) 
 III 17 (48%) 32 (60%) 19 (38%) 8 (17%) 8 (40%) 13 (38%) 
  p=0.438 P=0.04 P=0.88 
Nodal status Negative 11 (37%) nd 22(47%) 29 (58%) Nd Nd 
 Positive 19 (63%) nd 25(53%) 21 (42%) Nd Nd 
Family history Negative 25 (86%) nd 26 (76%) Nd 11 (55%) 22 (65%) 
 Breast/ovarian 
cancer 1 (3%) 
nd 8/34 (24%) 5/30 (17%) 8 (40%) 9 (26%) 
 Other cancers 3 (10%) nd nd Nd 1 (5%) Nd 
ER Negative 19 (58%) 23 (43%) 23 (46%) 11 (20%) 2 (10%) 7 (21%) 
 Positive 14 (42%) 31 (57%) 27 (54%) 39 (80%) 18 (90%) 27 (79%) 
  p=0.175 P=0.01 P=0.31 
PgR Negative 19 (58%) 25 (46%) 25 (50%) 16 (30%) 4 (20%) 10 (30%) 
 Positive 14 (42%) 29 (54%) 25 (50%) 34 (70%) 16 (80%) 23 (70%) 
  p=0.307 P=0.067 P=0.41 
HER-2/neu Not amplified 27 (77%) 43 (80%) 26 (52%) 37 (74%) 7 (35%) 21 (62%) 
 Amplified 8 (23%) 11 (20%) 24 (48%) 13 (26%) 13 (65%) 13 (38%) 
  p=0.78 P=0.03 P=0.06 
EGFR Negative 23 (70%) nd nd Nd Nd Nd 
 Membranous 10 (30%) nd nd Nd Nd Nd 
CK5/6 Negative 27 (77%) nd nd Nd Nd Nd 
 Positive 8 (23%) nd nd Nd Nd Nd 
p53 Negative 21 (62%) 39 (72%) 35 (70%) 46 (92%) 16 (84%) 28 (82%) 
 Positive 13 (38%) 15 (28%) 15 (30%) 4 (8%) 3 (16%) 6 (18%) 
  p=0.305 P=0.01 P=0.86 
Ki67 Low  9 (26%) 30 (56%) nd Nd 12 (60%) 25 (74%) 
 High  26 (74%) 24 (44%) nd nd 8 (40%) 9 (26%) 
  p= 0.006   P=0.30 
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Table 3. Frequencies of Discrete Clinicopathological Features of Early Onset Indonesian Breast Cancers
(< 40 Years) According to BRCA1/2 Mutation Status
pathological prognostic factors in a series of 35
invasive breast cancer patients below 40 years of
age and compared them with a control group of
postmenopausal aged over 50 years.
The results of our study show that breast
carcinoma in Indonesian women below 40 years of
age differ especially in proliferation as measured by
Ki67 positivity. As rate of proliferation is of overriding
prognostic importance and the most important
component of grade28, this is consistent with those
studies showing higher prevalence of grade 3
cancers29,30 and worse prognosis in young
women3,26,31, although Rodrigues et al.,30 found no
significance for Ki67 in their study. Grade itself was
not significant in our study, and the results on grade
in the literature and conflicting.29,30 ER, PR, p53 and
HER-2/neu were not significant in our study as well,
and also for these features other studies are
conflicting.29,30
Early onset breast cancer is often hereditary.32
In recent years, the histopathological features of
BRCA1 germline mutation related tumors have been
well characterized. They are most frequently of ductal
and medullary histological type6, more frequently
poorly differentiated6,17,33,34,35,36, usually
ER14,17,34,35,36,37,38, PR14,34,35,36,39 and HER-2/neu40,41
negative, and show a high degree of positivity for
CK5/640, EGFR11,12,13 and p53 accumulation.39,42,43
Fully consistent with this, our few BRCA1 related
cases were advanced stage, ductal type, grade 3,
ER and HER-2/neu negative, and EGFR, CK5/6 and
p53 positive.
No Mutation BRCA Mutation BRCA1 Mutation BRCA2 Mutation 
Features n 
freq (%) freq (%) freq (%) freq (%) 
stage 30             
I/II 12 9 39 3 25 0 0 3 60 
III/IV 18 14 61 4 22 2 100 2 40 
type 30             
lob 2 2 9 0 0 0 0 0 0 
duc 28 21 91 7 100 2 100 5 100 
grade 29             
well 3 3 14 0 0 0 0 0 0 
mod 11 7 32 4 57 0 0 4 80 
poor 15 12 55 3 43 2 100 1 20 
nodal status 29                 
negative 10 8 36 2 29 1 50 1 20 
positive 19 14 64 5 71 1 50 4 80 
Fam 
history 29                 
no  25 22 100 3 43 1 50 2 40 
yes 1 0 0 1 14 1 50 0 0 
other 3 0 0 3 43 0 0 3 60 
    p= 0.025         
ER 28                 
negative 15 11 52 4 57 2 100 2 40 
positive 13 10 48 3 43 0 0 3 60 
PgR 28             
negative 14 11 52 3 43 1 50 2 40 
positive 14 10 48 4 57 1 50 3 60 
her2 30             
not ampl 23 17 74 6 86 2 100 4 80 
amplified 7 6 26 1 14 0 0 1 20 
EGFR 28             
negative 19 16 76 3 43 0 0 3 60 
positive 9 5 24 4 57 2 100 2 40 
CK5/6 30             
negative 24 20 87 4 57 0 0 4 80 
positive 6 3 13 3 43 2 100 1 20 
p53 29                 
negative 18 15 68 3 43 0 0 3 60 
positive 11 7 32 4 57 2 100 2 40 
Ki67 30                 
negative 8 7 30 1 14 1 50 0 0 
positive 22 16 70 6 86 1 50 5 100 
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The phenotype and genotype of breast cancers
in BRCA2-mutation carriers seems to be less
outspoken and lies between that of BRCA1 mutation
carriers and sporadic controls.19 Better defining the
phenotype of BRCA2 related breast cancers is
especially important in Asian populations like ours,
as the prevalence of BRCA2 related cancers
exceeds that of BRCA1 related cancers.24 BRCA2
tumors are more frequently of ductal type44 as in the
present study where all BRCA2 related tumors were
ductal. They are also more frequently grade 2 and 3
than sporadic controls.6,34,35  In line with these previous
studies, BRCA2 carriers had in the present study
moderately or poorly differentiated tumors and none
of them were well differentiated. The frequency of
ER and PR expression in BRCA2 tumors has been
reported as similar to that in sporadic breast tumors
most studies14,35,36,39, in line with the present study.
As to p53, some studies have found p53
accumulation in around 20-50% of BRCA2 related
carcinomas.14 In the present study, 60% of the
BRCA2 associated tumors showed p53
accumulation. Data on HER-2/neu expression in
BRCA2-associated tumors vary from series to series,
probably as a consequence of differences in the
techniques employed. For example, Armes et
al.39and Eerola et al.36 found no differences in the
expression of HER-2/neu in BRCA2 and sporadic
breast tumors. However, other studies revealed low
frequencies between 0 and 3% in HER-2/neu over
expression in BRCA2 tumors.14,17,35 Combining
immunohistochemistry with a new amplification test,
we found a 20% frequency of HER-2/neu positivity
in BRCA2 associated tumors.
Concerning cytokeratin 5/6, 20% of our BRCA2
cases were positive, compared to 15.4% (N=48) in
the literature.13 There are few data on EGFR and
Ki67 index in breast cancers of BRCA2 mutated
cases. One study reported a 100% EGFR positivity19
in BRCA2 related breast cancer (N=5), another one
8% (N=48)13 compared to 40% in the present study.
As to Ki67, one study reported a median Ki67 of
20% in BRCA2 cancers, a little lower than the 37%
mean in our study. These studies, like ours, concern
however just a few cases, so these results will not
be significantly different.
The results of the present study add to the
concept that breast cancer arising in BRCA1 and
BRCA2 mutation carriers of mutation in the genes
differ from sporadic breast cancer of age matched
controls. This is especially clear for BRCA1 related
cancers. Unfortunately, also our study has not firmly
established a clear phenotype for BRCA2 related
breast cancers. One of the most important
applications of this information would be its use as
a guide for genetic testing. Although we have
developed a fast and relatively cheap method for
BRCA1/2 mutation detection20, such testing is still
difficult to afford for most Indonesian patients.
Currently, young age and positive family history are
the best predictors of a high likelihood of carrying a
BRCA1/2 mutation. However, to optimize screening,
it would for early onset Indonesian patients that are
often oblivious to their family history be quite useful
if histopathological features, in conjunction with
clinical data, could be used to raise the a priori chance
of a germline mutation (Table 3). To this end, the
strongest features pointing to a sporadic cancer
seem to be grade I and lobular differentiation.
Features increasing the chance of a germline BRCA1/
2 mutation are CK5/6 and EGFR expression, p53
accumulation and high proliferation as measured by
Ki67 labeling.
In conclusion, early onset Indonesian breast
cancer is characterized by increased proliferation.
Within the early onset group, the strongest features
pointing to a sporadic cancer seem to be the absence
of family history of breast and or ovarian cancer,
grade I and lobular differentiation. Features increasing
the chance of a germline BRCA1/2 mutation are
family history of breast and or ovarian cancer, CK5/
6 and EGFR expression, p53 accumulation and high
proliferation as measured by Ki67 labeling. This may
be potentially useful to optimize selection of early
onset breast cancer patients for BRCA1/2 mutation
testing.
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